Contact Us    |      Join    |

"The Voice of Oncology in Massachusetts"

Genmab & AbbVie announce EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

June 27, 2024 10:34 AM | Katy Monaco (Administrator)

Genmab and AbbVie announce that the FDA has approved  EPKINLY® (epcoritamab-bysp) for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. With this approval, EPKINLY is the first and only T-cell engaging bispecific antibody administered subcutaneously approved in the U.S. to treat this patient population. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial(s). Read More


860 Winter Street, Waltham, MA, 02451


tel: 781.434.7329

Massachusetts Society of Clinical Oncologists ©2024

Powered by Wild Apricot Membership Software